Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma
The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma. The European brand name for the drug is expected to be “Imnovid,” although final...
View ArticleKyprolis Or Pomalyst For Dual-Refractory Myeloma - What Is The Survival Impact?
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid....
View ArticleResearchers Publish Final Results Of Pomalyst Trial That Led To Approval In...
Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with...
View ArticlePomalyst-Cyclophosphamide-Prednisone Combination Effective And Safe In...
Results from a recent Italian Phase 1/2 clinical trial indicate that the combination of Pomalyst, cyclophosphamide, and prednisone is effective and safe in relapsed and refractory multiple...
View Article